Skip to main content
Top
Published in: Sports Medicine 6/2008

01-06-2008 | Review Article

Anabolic Steroid Use

Patterns of Use and Detection of Doping

Authors: Michael R. Graham, Bruce Davies, Fergal M. Grace, Andrew Kicman, Prof Julien S. Baker

Published in: Sports Medicine | Issue 6/2008

Login to get access

Abstract

Anabolic-androgenic steroids (AAS) were the first identified doping agents that have ergogenic effects and are being used to increase muscle mass and strength in adult males. Consequently, athletes are still using them to increase physical performance and bodybuilders are using them to improve size and cosmetic appearance. The prevalence of AAS use has risen dramatically over the last two decades and filtered into all aspects of society. Support for AAS users has increased, but not by the medical profession, who will not accept that AAS use dependency is a psychiatric condition. The adverse effects and potential dangers of AAS use have been well documented. AAS are used in sport by individuals who have acquired knowledge of the half-lives of specific drugs and the dosages and cycles required to avoid detection. Conversely, they are used by bodybuilders in extreme dosages with the intention of gaining muscle mass and size, with little or no regard for the consequences. Polypharmacy by self-prescription is prevalent in this sector. Most recently, AAS use has filtered through to ‘recreational street drug’ users and is the largest growth of drugs in this subdivision. They are taken to counteract the anorexic and cachectic effects of the illegal psychotropic street drugs. Screening procedures for AAS in World Anti-Doping Agency accredited laboratories are comprehensive and sensitive and are based mainly on gas chromatography-mass spectrometry, although liquid chromatography-mass spectrometry is becoming increasingly more valuable. The use of carbon isotope mass spectrometry is also of increasing importance in the detection of natural androgen administration, particularly to detect testosterone administration. There is a degree of contentiousness in the scenario of AAS drug use, both within and outside sport. AAS and associated doping agents are not illegal per se. Possession is not an offence, despite contravening sporting regulations and moral codes. Until AAS are classified in the same capacity as street drugs in the UK, where possession becomes a criminal offence, they will continue to attract those who want to win at any cost. The knowledge acquired by such work can only assist in the education of individuals who use such doping agents, with a view to minimizing health risks and hopefully once again create a level playing field in sport.
Literature
1.
go back to reference Haupt HA, Rovere GD. Anabolic steroids: a review of the literature. Am J Sports Med 1984; 12: 469–84PubMedCrossRef Haupt HA, Rovere GD. Anabolic steroids: a review of the literature. Am J Sports Med 1984; 12: 469–84PubMedCrossRef
2.
go back to reference Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic—androgenic steroids. Clin Ther 2001; 23: 1355–90PubMedCrossRef Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic—androgenic steroids. Clin Ther 2001; 23: 1355–90PubMedCrossRef
3.
go back to reference Kicman AT, Gower DB. Anabolic steroids in sport: biochemical, clinical and analytical perspectives. Ann Clin Biochem 2003; 40: 321–56PubMedCrossRef Kicman AT, Gower DB. Anabolic steroids in sport: biochemical, clinical and analytical perspectives. Ann Clin Biochem 2003; 40: 321–56PubMedCrossRef
4.
go back to reference Wilson JD, Leihy MW, Shaw G, et al. Androgen physiology: unsolved problems at the millennium. Mol Cell Endocrinol 2002; 198: 1–5PubMedCrossRef Wilson JD, Leihy MW, Shaw G, et al. Androgen physiology: unsolved problems at the millennium. Mol Cell Endocrinol 2002; 198: 1–5PubMedCrossRef
5.
go back to reference Janne OA, Palvimo JJ, Kallio P, et al. Androgen receptor and mechanism of androgen action. Ann Med 1993; 25: 83–9PubMedCrossRef Janne OA, Palvimo JJ, Kallio P, et al. Androgen receptor and mechanism of androgen action. Ann Med 1993; 25: 83–9PubMedCrossRef
6.
go back to reference Bruchovsky N, Wilson JD. The conversion of testosterone to 5−alpha—androstan−17−beta—ol−3−one by rat prostate in vivo and in vitro. J Biol Chem 1968; 243: 2012–21PubMed Bruchovsky N, Wilson JD. The conversion of testosterone to 5−alpha—androstan−17−beta—ol−3−one by rat prostate in vivo and in vitro. J Biol Chem 1968; 243: 2012–21PubMed
7.
go back to reference Deslypere JP, Young M, Wilson JD, et al. Testosterone and 5 alpha—dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV—CAT reporter gene. Mol Cell Endocrinol 1992; 88: 15–22PubMedCrossRef Deslypere JP, Young M, Wilson JD, et al. Testosterone and 5 alpha—dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV—CAT reporter gene. Mol Cell Endocrinol 1992; 88: 15–22PubMedCrossRef
8.
go back to reference Wilson JD, Griffin JE, Russell DW. Steroid 5 alpha—reductase 2 deficiency. Endocr Rev 1993; 14: 577–93PubMed Wilson JD, Griffin JE, Russell DW. Steroid 5 alpha—reductase 2 deficiency. Endocr Rev 1993; 14: 577–93PubMed
9.
go back to reference Kroon FJ, Munday PL, Westcott DA, et al. Aromatase pathway mediates sex change in each direction. Proc Biol Sci 2005; 272: 1399–405PubMedCrossRef Kroon FJ, Munday PL, Westcott DA, et al. Aromatase pathway mediates sex change in each direction. Proc Biol Sci 2005; 272: 1399–405PubMedCrossRef
10.
go back to reference Ruckzika L, Wettstein A, Kaegi H, et al. Sexual hormone VIII Darstellung von Testosterone unter Anwendung gemischter Ester. Helv Chim Acta 1935; 18: 1478CrossRef Ruckzika L, Wettstein A, Kaegi H, et al. Sexual hormone VIII Darstellung von Testosterone unter Anwendung gemischter Ester. Helv Chim Acta 1935; 18: 1478CrossRef
11.
go back to reference Di Pasquale MG. Anabolic steroid side—effects: facts, fiction and treatment. Warkworth (ON): MGD Press, 1990 Di Pasquale MG. Anabolic steroid side—effects: facts, fiction and treatment. Warkworth (ON): MGD Press, 1990
12.
go back to reference Cicardi M, Bergamischini L, Tucci A, et al. Morphological evaluation of the liver in hereditary angioedema patients on long—term treatment with androgen derivatives. J Allergy Clin Immunol 1983; 72: 294–8PubMedCrossRef Cicardi M, Bergamischini L, Tucci A, et al. Morphological evaluation of the liver in hereditary angioedema patients on long—term treatment with androgen derivatives. J Allergy Clin Immunol 1983; 72: 294–8PubMedCrossRef
13.
go back to reference Van Eenoo P, Delbeke FT. Metabolism and excretion of anabolic steroids in doping control: new steroids and new insights. J Steroid Biochem Mol Biol 2006; 101: 161–78PubMedCrossRef Van Eenoo P, Delbeke FT. Metabolism and excretion of anabolic steroids in doping control: new steroids and new insights. J Steroid Biochem Mol Biol 2006; 101: 161–78PubMedCrossRef
14.
go back to reference Bardin CW, Lipsett MB. Testosterone and androstenedione blood production rates in normal women and women with idiopathic hirsutism or polycystic ovaries. J Clin Invest 1967; 46: 891–902PubMedCrossRef Bardin CW, Lipsett MB. Testosterone and androstenedione blood production rates in normal women and women with idiopathic hirsutism or polycystic ovaries. J Clin Invest 1967; 46: 891–902PubMedCrossRef
15.
go back to reference Horton R, Tait JF. Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. J Clin Invest 1966; 45: 301–13PubMedCrossRef Horton R, Tait JF. Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. J Clin Invest 1966; 45: 301–13PubMedCrossRef
16.
go back to reference Bassindale T, Cowan DA. Effects of oral administration of androstenedione on plasma androgens in young women using hormonal contraception. J Clin Endocrinol Metab 2004; 89: 6030–8PubMedCrossRef Bassindale T, Cowan DA. Effects of oral administration of androstenedione on plasma androgens in young women using hormonal contraception. J Clin Endocrinol Metab 2004; 89: 6030–8PubMedCrossRef
17.
go back to reference Brown GA, Dewey JC, Brunkhorst JA, et al. Changes in serum testosterone and estradiol concentrations following acute androstenedione ingestion in young women. Horm Metab Res 2004; 36: 62–6PubMedCrossRef Brown GA, Dewey JC, Brunkhorst JA, et al. Changes in serum testosterone and estradiol concentrations following acute androstenedione ingestion in young women. Horm Metab Res 2004; 36: 62–6PubMedCrossRef
18.
go back to reference Kicman AT, Bassindale T, Cowan DA, et al. Effect of androstenedione ingestion on plasma testosterone in young women; a dietary supplement with potential health risks. Clin Chem 2003; 49: 167–9PubMedCrossRef Kicman AT, Bassindale T, Cowan DA, et al. Effect of androstenedione ingestion on plasma testosterone in young women; a dietary supplement with potential health risks. Clin Chem 2003; 49: 167–9PubMedCrossRef
19.
go back to reference Leder BZ, Leblanc KM, Longcope C, et al. Effects of oral androstenedione administration on serum testosterone and estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 5449–54PubMedCrossRef Leder BZ, Leblanc KM, Longcope C, et al. Effects of oral androstenedione administration on serum testosterone and estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 5449–54PubMedCrossRef
20.
go back to reference Miyamoto H, Yeh S, Lardy H, et al. Delta 5−androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 1998; 95: 11083–8PubMedCrossRef Miyamoto H, Yeh S, Lardy H, et al. Delta 5−androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 1998; 95: 11083–8PubMedCrossRef
21.
go back to reference Van der Vies J. Pharmacokinetics of anabolic steroids. Wien Med Wochenschr 1993; 143: 366–8PubMed Van der Vies J. Pharmacokinetics of anabolic steroids. Wien Med Wochenschr 1993; 143: 366–8PubMed
22.
go back to reference Hartgens F, Rietjens G, Keizer HA, et al. Effects of androgenic anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med 2004; 38: 253–9PubMedCrossRef Hartgens F, Rietjens G, Keizer HA, et al. Effects of androgenic anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med 2004; 38: 253–9PubMedCrossRef
23.
go back to reference Taylor WN. Anabolic steroids and the athlete. Jefferson (NC): Mcfarland, 1982 Taylor WN. Anabolic steroids and the athlete. Jefferson (NC): Mcfarland, 1982
24.
go back to reference Franke WW, Berendonk B. Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem 1997; 43: 1262–79PubMed Franke WW, Berendonk B. Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem 1997; 43: 1262–79PubMed
25.
go back to reference Kicman AT, Brooks RV, Collyer SC, et al. Criteria to indicate testosterone administration. Br J Sports Med 1990; 24: 253–64PubMedCrossRef Kicman AT, Brooks RV, Collyer SC, et al. Criteria to indicate testosterone administration. Br J Sports Med 1990; 24: 253–64PubMedCrossRef
26.
go back to reference Dehennin L. Detection of simultaneous self—administration of testosterone and epitestosterone in healthy men. Clin Chem 1994; 40: 106–9PubMed Dehennin L. Detection of simultaneous self—administration of testosterone and epitestosterone in healthy men. Clin Chem 1994; 40: 106–9PubMed
27.
go back to reference Perry PJ, Mac Indoe JH, Yates WR, et al. Detection of anabolic steroid administration: ratio of urinary testosterone to epitestosterone vs the ratio of urinary testosterone to luteinizing hormone. Clin Chem 1997; 43: 731–5PubMed Perry PJ, Mac Indoe JH, Yates WR, et al. Detection of anabolic steroid administration: ratio of urinary testosterone to epitestosterone vs the ratio of urinary testosterone to luteinizing hormone. Clin Chem 1997; 43: 731–5PubMed
28.
go back to reference Catlin DH, Sekera MH, Ahrens BD, et al. Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid Commun Mass Spectrom 2004; 18: 1245–9PubMedCrossRef Catlin DH, Sekera MH, Ahrens BD, et al. Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid Commun Mass Spectrom 2004; 18: 1245–9PubMedCrossRef
29.
go back to reference Catlin DH, Ahrens BD, et al. Detection of norbolethone, an anabolic steroid never marketed, in athletes’ urine. Rapid Commun Mass Spectrom 2002; 16: 1273–5PubMedCrossRef Catlin DH, Ahrens BD, et al. Detection of norbolethone, an anabolic steroid never marketed, in athletes’ urine. Rapid Commun Mass Spectrom 2002; 16: 1273–5PubMedCrossRef
30.
go back to reference Sekera MH, Ahrens BD, Chang YC. Another designer steroid: discovery, synthesis, and detection of ‘madol’ in urine. Rapid Commun Mass Spectrom 2005; 19: 781–4PubMedCrossRef Sekera MH, Ahrens BD, Chang YC. Another designer steroid: discovery, synthesis, and detection of ‘madol’ in urine. Rapid Commun Mass Spectrom 2005; 19: 781–4PubMedCrossRef
31.
go back to reference Hershberger LG, Shipley EG, Meyer RK. Myotrophic activity of 19−nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exp Biol Med 1953; 83: 175–80PubMed Hershberger LG, Shipley EG, Meyer RK. Myotrophic activity of 19−nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exp Biol Med 1953; 83: 175–80PubMed
32.
go back to reference Tomoda H. Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation. Am J Cardiol 1999; 83: 123–5PubMedCrossRef Tomoda H. Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation. Am J Cardiol 1999; 83: 123–5PubMedCrossRef
33.
go back to reference British National Formulary. A joint publication of the British Medical Association and the Royal Pharmaceutical Society of Great Britain. BMJ Group and RPS Publishing, 2007 [online]. Available from URL: (http://www.bnf.org) [Accessed 2008 Apr 23] British National Formulary. A joint publication of the British Medical Association and the Royal Pharmaceutical Society of Great Britain. BMJ Group and RPS Publishing, 2007 [online]. Available from URL: (http://​www.​bnf.​org) [Accessed 2008 Apr 23]
34.
go back to reference Hengge UR, Baumann M, Maleba R, et al. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV—1) infection. Br J Nutr 1996; 75: 129–38PubMedCrossRef Hengge UR, Baumann M, Maleba R, et al. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV—1) infection. Br J Nutr 1996; 75: 129–38PubMedCrossRef
35.
go back to reference Bhasin S, Javanbakht M. Can androgen therapy replete lean body mass and improve muscle function in wasting associated with human immunodeficiency virus infection? J Parenter Enteral Nutr 1999; 23: 195–201CrossRef Bhasin S, Javanbakht M. Can androgen therapy replete lean body mass and improve muscle function in wasting associated with human immunodeficiency virus infection? J Parenter Enteral Nutr 1999; 23: 195–201CrossRef
36.
go back to reference Bogin V, Shaw-Stiffel T. Androgenic anabolic steroids and other therapies for HIV—related wasting. J Clin Ligand Assay 1999; 22: 268–78 Bogin V, Shaw-Stiffel T. Androgenic anabolic steroids and other therapies for HIV—related wasting. J Clin Ligand Assay 1999; 22: 268–78
37.
go back to reference Bhasin S, Storer TW, Javanbakht M, et al. Testosterone replacement and resistance exercise in HIV—infected men with weight loss and low testosterone levels. JAMA 2000; 283: 763–70PubMedCrossRef Bhasin S, Storer TW, Javanbakht M, et al. Testosterone replacement and resistance exercise in HIV—infected men with weight loss and low testosterone levels. JAMA 2000; 283: 763–70PubMedCrossRef
38.
go back to reference Gold J, Batterham MJ, Rekers H, et al. Effects of nandrolone decanoate compared with placebo or testosterone on HIV associated wasting. HIV Med 2006; 7: 146–55PubMedCrossRef Gold J, Batterham MJ, Rekers H, et al. Effects of nandrolone decanoate compared with placebo or testosterone on HIV associated wasting. HIV Med 2006; 7: 146–55PubMedCrossRef
39.
go back to reference Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999; 281: 1275–81PubMedCrossRef Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999; 281: 1275–81PubMedCrossRef
40.
go back to reference Johansen KL, Painter PL, Sakkas GK, et al. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J Am Soc Nephrol 2006; 17: 2307–14PubMedCrossRef Johansen KL, Painter PL, Sakkas GK, et al. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J Am Soc Nephrol 2006; 17: 2307–14PubMedCrossRef
41.
go back to reference Bhasin S, Calof OM, Storer TW, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2006; 2: 146–59PubMedCrossRef Bhasin S, Calof OM, Storer TW, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2006; 2: 146–59PubMedCrossRef
42.
go back to reference Solomon AM, Bouloux PMG. Modifying muscle mass: the endocrine perspective. J Endocrinol 2006; 191: 349–60PubMedCrossRef Solomon AM, Bouloux PMG. Modifying muscle mass: the endocrine perspective. J Endocrinol 2006; 191: 349–60PubMedCrossRef
43.
go back to reference Ferreira IM, Verreschi IT, Nery LE, et al. The influence of 6 months of oral AAS on body mass and respiratory muscles in undernourished COPD patients. Chest 1998; 114: 19–28PubMedCrossRef Ferreira IM, Verreschi IT, Nery LE, et al. The influence of 6 months of oral AAS on body mass and respiratory muscles in undernourished COPD patients. Chest 1998; 114: 19–28PubMedCrossRef
44.
go back to reference Demling RH. The role of anabolic hormones for wound healing in catabolic states. J Burn Wounds 2005; 4: 2 Demling RH. The role of anabolic hormones for wound healing in catabolic states. J Burn Wounds 2005; 4: 2
45.
go back to reference Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003; 24: 313–40PubMedCrossRef Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003; 24: 313–40PubMedCrossRef
46.
go back to reference Bhasin M, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1–7PubMedCrossRef Bhasin M, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1–7PubMedCrossRef
47.
48.
go back to reference Windsor RE, Dumitru D. Anabolic steroid use by athletes. Postgrad Med 1988; 84: 37–49PubMed Windsor RE, Dumitru D. Anabolic steroid use by athletes. Postgrad Med 1988; 84: 37–49PubMed
49.
go back to reference Hickson RC, Ball KL, Falduto HT. Adverse effects of anabolic steroids. Med Toxicol Adverse Drug Exp 1989; 4: 254–68PubMedCrossRef Hickson RC, Ball KL, Falduto HT. Adverse effects of anabolic steroids. Med Toxicol Adverse Drug Exp 1989; 4: 254–68PubMedCrossRef
50.
go back to reference Ulmark R, Blonstein JL. The dangers of doping. J Sports Med Phys Fitness 1963; 44: 248–9PubMed Ulmark R, Blonstein JL. The dangers of doping. J Sports Med Phys Fitness 1963; 44: 248–9PubMed
51.
go back to reference Todd T. Anabolic steroids: the gremlins of sport. J Sport History 1987; 14: 87–107 Todd T. Anabolic steroids: the gremlins of sport. J Sport History 1987; 14: 87–107
52.
go back to reference Pope Jr HG, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiatry 1988; 145: 487–90PubMed Pope Jr HG, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiatry 1988; 145: 487–90PubMed
53.
go back to reference Pope Jr HG, Katz DL. Homicide and near—homicide by anabolic steroid users. J Clin Psychiatry 1990; 51: 28–31PubMed Pope Jr HG, Katz DL. Homicide and near—homicide by anabolic steroid users. J Clin Psychiatry 1990; 51: 28–31PubMed
54.
go back to reference Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med 1999; 17: 851–7PubMedCrossRef Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med 1999; 17: 851–7PubMedCrossRef
55.
go back to reference Kuipers H, Wijnen JA, Hartgens F, et al. Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body—builders. Int J Sports Med 1991; 12: 413–8PubMedCrossRef Kuipers H, Wijnen JA, Hartgens F, et al. Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body—builders. Int J Sports Med 1991; 12: 413–8PubMedCrossRef
56.
go back to reference Sader MA, Griffiths KA, Mc Credie RJ, et al. Androgenic anabolic steroids and arterial structure and function in male body—builders. J Am Coll Cardiol 2001; 37: 224–30PubMedCrossRef Sader MA, Griffiths KA, Mc Credie RJ, et al. Androgenic anabolic steroids and arterial structure and function in male body—builders. J Am Coll Cardiol 2001; 37: 224–30PubMedCrossRef
57.
go back to reference Lloyd FH, Powell P, Murdoch AP. Anabolic steroid abuse by body builders and male subfertility. BMJ 1996; 313: 100–1PubMedCrossRef Lloyd FH, Powell P, Murdoch AP. Anabolic steroid abuse by body builders and male subfertility. BMJ 1996; 313: 100–1PubMedCrossRef
58.
go back to reference Grace FM, Baker JS, Davies B. Anabolic androgenic steroid (AAS) use in recreational gym users: a regional sample of the Mid—Glamorgan area. J Subst Use 2001; 6: 189–95CrossRef Grace FM, Baker JS, Davies B. Anabolic androgenic steroid (AAS) use in recreational gym users: a regional sample of the Mid—Glamorgan area. J Subst Use 2001; 6: 189–95CrossRef
59.
go back to reference Graham MR, Davies B, Kicman A, et al. Recombinant human growth hormone in abstinent androgenic—anabolic steroid use: psychological, endocrine and trophic factor effects. Curr Neurovasc Res 2007; 4 (1): 9–18PubMedCrossRef Graham MR, Davies B, Kicman A, et al. Recombinant human growth hormone in abstinent androgenic—anabolic steroid use: psychological, endocrine and trophic factor effects. Curr Neurovasc Res 2007; 4 (1): 9–18PubMedCrossRef
60.
go back to reference Parrott AC, Choi PY, Davies M. Anabolic steroid use by amateur athletes: effects upon psychological mood states. J Sports Med Phys Fitness 1994; 34: 292–8PubMed Parrott AC, Choi PY, Davies M. Anabolic steroid use by amateur athletes: effects upon psychological mood states. J Sports Med Phys Fitness 1994; 34: 292–8PubMed
61.
go back to reference Perry H, Littlepage B. Dying to be big: a review of anabolic steroid use. Br J Sports Med 1992; 4: 259–61CrossRef Perry H, Littlepage B. Dying to be big: a review of anabolic steroid use. Br J Sports Med 1992; 4: 259–61CrossRef
62.
go back to reference Korkia P, Stimson GV. Anabolic steroid use in Great Britain: an exploratory investigation. London: The Centre for Research on Drugs and Health Behaviour, 1993 Korkia P, Stimson GV. Anabolic steroid use in Great Britain: an exploratory investigation. London: The Centre for Research on Drugs and Health Behaviour, 1993
63.
go back to reference Pates R, Barry C. Steroid use in Cardiff: a problem for whom? J Perform Enhanc Drugs 1996; 1: 92–7 Pates R, Barry C. Steroid use in Cardiff: a problem for whom? J Perform Enhanc Drugs 1996; 1: 92–7
64.
go back to reference Melia P, Pipe A, Greenberg L. The use of anabolic—androgenic steroids by Canadian students. Clin J Sport Med 1996; 6: 9–14PubMedCrossRef Melia P, Pipe A, Greenberg L. The use of anabolic—androgenic steroids by Canadian students. Clin J Sport Med 1996; 6: 9–14PubMedCrossRef
65.
66.
go back to reference Baker JS, Graham MR, Davies B. ‘steroid’ and prescription medicine abuse in the health and fitness community: a regional study. Eur J Int Med 2006; 17: 479–84CrossRef Baker JS, Graham MR, Davies B. ‘steroid’ and prescription medicine abuse in the health and fitness community: a regional study. Eur J Int Med 2006; 17: 479–84CrossRef
67.
go back to reference Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 2006; 38: 644–51PubMedCrossRef Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 2006; 38: 644–51PubMedCrossRef
69.
go back to reference Kanayama G, Cohane GH, Weiss RD, et al. Past anabolic androgenic steroid use among men admitted for substance abuse treatment: an under recognized problem. J Clin Psychiatry 2003; 64: 156–60PubMedCrossRef Kanayama G, Cohane GH, Weiss RD, et al. Past anabolic androgenic steroid use among men admitted for substance abuse treatment: an under recognized problem. J Clin Psychiatry 2003; 64: 156–60PubMedCrossRef
70.
go back to reference Graham MR, Grace FM, Boobier W, et al. Homocysteine induced cardiovascular events: a consequence of long—term anabolic—androgenic steroid (AAS) abuse. Br J Sports Med 2006; 40: 644–8PubMedCrossRef Graham MR, Grace FM, Boobier W, et al. Homocysteine induced cardiovascular events: a consequence of long—term anabolic—androgenic steroid (AAS) abuse. Br J Sports Med 2006; 40: 644–8PubMedCrossRef
72.
go back to reference Kicman AT, Fallon JK, Cowan DA, et al. Candida albicans can produce testosterone: impact on the T/E sports drug test. Clin Chem 2002; 10: 1799–801 Kicman AT, Fallon JK, Cowan DA, et al. Candida albicans can produce testosterone: impact on the T/E sports drug test. Clin Chem 2002; 10: 1799–801
73.
go back to reference Abraham GE. Solid—phase radioimmunoassay of estradiol−17−β. J Clin Endocrinol Metab 1969; 29: 866–70PubMedCrossRef Abraham GE. Solid—phase radioimmunoassay of estradiol−17−β. J Clin Endocrinol Metab 1969; 29: 866–70PubMedCrossRef
74.
go back to reference Brooks RV, Firth RG, Sumner NA. Detection of anabolic steroids by radioimmunoassay. Br J Sports Med 1975; 9: 89–92PubMedCrossRef Brooks RV, Firth RG, Sumner NA. Detection of anabolic steroids by radioimmunoassay. Br J Sports Med 1975; 9: 89–92PubMedCrossRef
75.
go back to reference Ward RJ, Shackleton CH, Lawson AM. Gas chromatographicmass spectrometric methods for the detection and identification of anabolic steroid drugs. Br J Sports Med 1975; 9: 93–7PubMedCrossRef Ward RJ, Shackleton CH, Lawson AM. Gas chromatographicmass spectrometric methods for the detection and identification of anabolic steroid drugs. Br J Sports Med 1975; 9: 93–7PubMedCrossRef
76.
go back to reference Brooks RV, Jeremiah G, Webb WA, et al. Detection of anabolic steroid administration to athletes. J Steroid Biochem 1979; 11: 913–7PubMedCrossRef Brooks RV, Jeremiah G, Webb WA, et al. Detection of anabolic steroid administration to athletes. J Steroid Biochem 1979; 11: 913–7PubMedCrossRef
77.
go back to reference Kicman AT, Brooks RV. Radioimmunoassay for nandrolone metabolites. J Pharm Biomed Anal 1988; 6: 473–83PubMedCrossRef Kicman AT, Brooks RV. Radioimmunoassay for nandrolone metabolites. J Pharm Biomed Anal 1988; 6: 473–83PubMedCrossRef
78.
go back to reference Catlin DH, Kammerer RC, Hatton CK, et al. Analytical chemistry at the Games of the XXIIIrd Olympiad in Los Angeles, 1984. Clin Chem 1987; 33: 319–27PubMed Catlin DH, Kammerer RC, Hatton CK, et al. Analytical chemistry at the Games of the XXIIIrd Olympiad in Los Angeles, 1984. Clin Chem 1987; 33: 319–27PubMed
79.
go back to reference Schanzer W, Donike M. Metabolism of anabolic steroids in man: synthesis and use of reference substances for identification of anabolic steroid metabolites. Anal Chim Acta 1993; 275: 23–48CrossRef Schanzer W, Donike M. Metabolism of anabolic steroids in man: synthesis and use of reference substances for identification of anabolic steroid metabolites. Anal Chim Acta 1993; 275: 23–48CrossRef
80.
go back to reference Bowers LD. Analytical advances in detection of performance enhancing compounds. Clin Chem 1997; 43: 1299–304PubMed Bowers LD. Analytical advances in detection of performance enhancing compounds. Clin Chem 1997; 43: 1299–304PubMed
81.
go back to reference Thevis M, Geyer H, Mareck U, et al. Screening for unknown synthetic steroids in human urine by liquid chromatographytandem mass spectrometry. J Mass Spectrom 2005; 40: 955–62PubMedCrossRef Thevis M, Geyer H, Mareck U, et al. Screening for unknown synthetic steroids in human urine by liquid chromatographytandem mass spectrometry. J Mass Spectrom 2005; 40: 955–62PubMedCrossRef
82.
go back to reference Becket A. Anecdotal evidence of drug abuse: drug abuse in sport. London: The Sports Council, 1985 Becket A. Anecdotal evidence of drug abuse: drug abuse in sport. London: The Sports Council, 1985
83.
go back to reference Cowan DA, Kicman AT. Doping in sport: misuse, analytical tests, and legal aspects [editorial]. Clin Chem 1997; 43: 1110–3PubMed Cowan DA, Kicman AT. Doping in sport: misuse, analytical tests, and legal aspects [editorial]. Clin Chem 1997; 43: 1110–3PubMed
84.
go back to reference Donike M, Barwald KR, Klosterman K, et al. Detection of exogenous testosterone [in Dutch]. In: Heck H, Hollman W, Liesen H, et al., editors. Sport: Leistung und Gesundheit, Kongressbd. Dtsch. Sportarztekongress. Koln: Deutscher Artze—Verlag, 1983: 293–8 Donike M, Barwald KR, Klosterman K, et al. Detection of exogenous testosterone [in Dutch]. In: Heck H, Hollman W, Liesen H, et al., editors. Sport: Leistung und Gesundheit, Kongressbd. Dtsch. Sportarztekongress. Koln: Deutscher Artze—Verlag, 1983: 293–8
86.
go back to reference Kicman AT, Oftebro H, Walker C, et al. Potential use of ketoconazole in a dynamic endocrine test to differentiate between biological outliers and testosterone use by athletes. Clin Chem 1993; 39: 1798–803PubMed Kicman AT, Oftebro H, Walker C, et al. Potential use of ketoconazole in a dynamic endocrine test to differentiate between biological outliers and testosterone use by athletes. Clin Chem 1993; 39: 1798–803PubMed
87.
go back to reference Raynaud E, Audran M, Pages JC, et al. Study of urinary excretion of testosterone and epitestosterone glucuronides in children and adolescents. Pathol Biol (Paris) 1993; 41: 159–63 Raynaud E, Audran M, Pages JC, et al. Study of urinary excretion of testosterone and epitestosterone glucuronides in children and adolescents. Pathol Biol (Paris) 1993; 41: 159–63
88.
go back to reference Raynaud E, Audran M, Pages JC, et al. Determination of urinary testosterone and epitestosterone during pubertal development: a cross—sectional study in 141 normal—male subjects. Clin Endocrinol 1993; 38: 353–9CrossRef Raynaud E, Audran M, Pages JC, et al. Determination of urinary testosterone and epitestosterone during pubertal development: a cross—sectional study in 141 normal—male subjects. Clin Endocrinol 1993; 38: 353–9CrossRef
89.
go back to reference Oftebro H, Jensen J, Mowinckel P, et al. Establishing a ketoconazole suppression test for verifying testosterone administration in the doping control of athletes. J Clin Endocrinol Metab 1994; 78: 973–7PubMedCrossRef Oftebro H, Jensen J, Mowinckel P, et al. Establishing a ketoconazole suppression test for verifying testosterone administration in the doping control of athletes. J Clin Endocrinol Metab 1994; 78: 973–7PubMedCrossRef
90.
go back to reference Garle M, Ocka R, Palonek E, et al. Increased urinary testosterone epitestosterone ratios found in Swedish athletes in connection with a national control programme: evaluation of 28 cases. J Chromatogr 1996; 687: 55–9CrossRef Garle M, Ocka R, Palonek E, et al. Increased urinary testosterone epitestosterone ratios found in Swedish athletes in connection with a national control programme: evaluation of 28 cases. J Chromatogr 1996; 687: 55–9CrossRef
91.
go back to reference Catlin DH, Hatton CK, Starcevic SH. Issues in detecting abuse of xenobiotic anabolic steroids and testosterone by analysis of athletes’ urine. Clin Chem 1997; 43: 1280–8PubMed Catlin DH, Hatton CK, Starcevic SH. Issues in detecting abuse of xenobiotic anabolic steroids and testosterone by analysis of athletes’ urine. Clin Chem 1997; 43: 1280–8PubMed
92.
go back to reference Becchi M, Aguilera R, Farizon Y, et al. Gas chromatography/combustion/isotope—ratio mass spectrometry analysis of urinary steroids to detect misuse of testosterone in sport. Rapid Commun Mass Spectrom 1994; 8: 304–8PubMedCrossRef Becchi M, Aguilera R, Farizon Y, et al. Gas chromatography/combustion/isotope—ratio mass spectrometry analysis of urinary steroids to detect misuse of testosterone in sport. Rapid Commun Mass Spectrom 1994; 8: 304–8PubMedCrossRef
93.
go back to reference Aguilera R, Becchi M, Casabianca H, et al. Improved method of detection of testosterone abuse by gas chromatography/combustion/isotope ratio mass spectrometry analysis of urinary steroids. J Mass Spectrom 1996; 31: 169–76PubMedCrossRef Aguilera R, Becchi M, Casabianca H, et al. Improved method of detection of testosterone abuse by gas chromatography/combustion/isotope ratio mass spectrometry analysis of urinary steroids. J Mass Spectrom 1996; 31: 169–76PubMedCrossRef
94.
go back to reference Aguilera R, Becchi M, Grenot C, et al. Detection of testosterone misuse: comparison of two chromatographic sample preparation methods for gas chromatographic—combustion/isotope ratio mass spectrometric analysis. J Chromatogr B 1996; 687: 43–53CrossRef Aguilera R, Becchi M, Grenot C, et al. Detection of testosterone misuse: comparison of two chromatographic sample preparation methods for gas chromatographic—combustion/isotope ratio mass spectrometric analysis. J Chromatogr B 1996; 687: 43–53CrossRef
95.
go back to reference Horning S, Geyer H, Schanzer W, et al. Detection of exogenous testosterone by 13C/12C analysis. In: Schanzer W, Geyer H, Gotzmann A, et al., editors. Recent advances in doping analysis: Proceedings of the 14th Cologne Workshop on Dope Analysis; 1996 Mar 17-22; Cologne. Cologne: Sport und Buch Strauss, 1997: 275–83 Horning S, Geyer H, Schanzer W, et al. Detection of exogenous testosterone by 13C/12C analysis. In: Schanzer W, Geyer H, Gotzmann A, et al., editors. Recent advances in doping analysis: Proceedings of the 14th Cologne Workshop on Dope Analysis; 1996 Mar 17-22; Cologne. Cologne: Sport und Buch Strauss, 1997: 275–83
96.
go back to reference Shackleton CH, Phillips A, Chang T, et al. Confirming testosterone administration by isotope ratio mass spectrometric analysis of urinary androstanediols. Steroids 1997; 62: 379–87PubMedCrossRef Shackleton CH, Phillips A, Chang T, et al. Confirming testosterone administration by isotope ratio mass spectrometric analysis of urinary androstanediols. Steroids 1997; 62: 379–87PubMedCrossRef
97.
go back to reference Horning S, Geyer H, Schanzer W, et al. Detection of exogenous steroids by 13C/12C analysis. In: Schanzer W, Geyer H, Gotzmann A, et al., editors. Recent advances in doping analysis: Proceedings of the 15th Cologne Workshop on Dope Analysis; 1997 Feb 23-28; Cologne. Cologne: Sport und Buch Strauss, 1998: 135–48 Horning S, Geyer H, Schanzer W, et al. Detection of exogenous steroids by 13C/12C analysis. In: Schanzer W, Geyer H, Gotzmann A, et al., editors. Recent advances in doping analysis: Proceedings of the 15th Cologne Workshop on Dope Analysis; 1997 Feb 23-28; Cologne. Cologne: Sport und Buch Strauss, 1998: 135–48
98.
go back to reference Aguilera R, Catlin DH, Becchi M, et al. Screening urine for exogenous testosterone by isotope ratio mass spectrometric analysis of one pregnanediol and two androstanediols. J Chromatogr B Analyt Technol Biomed Life Sci 1999; 727: 95–105CrossRef Aguilera R, Catlin DH, Becchi M, et al. Screening urine for exogenous testosterone by isotope ratio mass spectrometric analysis of one pregnanediol and two androstanediols. J Chromatogr B Analyt Technol Biomed Life Sci 1999; 727: 95–105CrossRef
99.
go back to reference Aguilera R, Chapman TE, Catlin DH. A rapid screening assay for measuring urinary androsterone and etiocholanolone delta (13)C (per thousand) values by gas chromatography/combustion/isotope ratio mass spectrometry. Rapid Commun Mass Spectrom 2000; 14: 2294–9PubMedCrossRef Aguilera R, Chapman TE, Catlin DH. A rapid screening assay for measuring urinary androsterone and etiocholanolone delta (13)C (per thousand) values by gas chromatography/combustion/isotope ratio mass spectrometry. Rapid Commun Mass Spectrom 2000; 14: 2294–9PubMedCrossRef
100.
go back to reference Aguilera R, Chapman TE, Starcevic B, et al. Performance characteristics of a carbon isotope ratio method for detecting doping with testosterone based on urine diols: controls and athletes with elevated testosterone/epitestosterone ratios. Clin Chem 2001; 47: 292–300PubMed Aguilera R, Chapman TE, Starcevic B, et al. Performance characteristics of a carbon isotope ratio method for detecting doping with testosterone based on urine diols: controls and athletes with elevated testosterone/epitestosterone ratios. Clin Chem 2001; 47: 292–300PubMed
101.
go back to reference Ayotte C, Goudreault D, Levesque JF, et al. GC/C/IRMS and GC/MS in ‘natural’ steroids testing. Proceedings of the Manfred Donike Workshop — Recent Advances in Doping Analysis (9); 1996 Mar 17-22; Cologne. Cologne: Sport und Buch Strauss, 2001 Ayotte C, Goudreault D, Levesque JF, et al. GC/C/IRMS and GC/MS in ‘natural’ steroids testing. Proceedings of the Manfred Donike Workshop — Recent Advances in Doping Analysis (9); 1996 Mar 17-22; Cologne. Cologne: Sport und Buch Strauss, 2001
102.
go back to reference de la Torre X, Gonzalez JC, Pichini S, et al. 13C/12C isotope ratio MS analysis of testosterone, in chemicals and pharmaceutical preparations. J Pharm Biomed Anal 2001; 24: 645–50PubMedCrossRef de la Torre X, Gonzalez JC, Pichini S, et al. 13C/12C isotope ratio MS analysis of testosterone, in chemicals and pharmaceutical preparations. J Pharm Biomed Anal 2001; 24: 645–50PubMedCrossRef
103.
go back to reference Trout GJ, Kazlauskas R. Sports drug testing: an analysts perspective. Chem Soc Rev 2004; 33: 1–13PubMedCrossRef Trout GJ, Kazlauskas R. Sports drug testing: an analysts perspective. Chem Soc Rev 2004; 33: 1–13PubMedCrossRef
104.
105.
go back to reference Bethune JE. The adrenal cortex: a scope monograph. Kalamazoo (MI): The Upjohn Company, 1975 Bethune JE. The adrenal cortex: a scope monograph. Kalamazoo (MI): The Upjohn Company, 1975
106.
go back to reference Grant JK, Beastall GH. Clinical biochemistry of steroid hormones. London: Croom Helm Ltd, 1983 Grant JK, Beastall GH. Clinical biochemistry of steroid hormones. London: Croom Helm Ltd, 1983
107.
go back to reference Brooks RV, Collyer SP, Kicman AT, et al. HCG doping in sport and methods for its detection. In: Bellotti P, Benzi G, Ljungqvist A, editors. IInd International Athletic Foundation World Symposium on Doping in Sport: Official Proceedings; 1989 Jun 5-7; Monte Carlo. Monte Carlo: International Athletic Foundation (IAF), 1990: 37–45 Brooks RV, Collyer SP, Kicman AT, et al. HCG doping in sport and methods for its detection. In: Bellotti P, Benzi G, Ljungqvist A, editors. IInd International Athletic Foundation World Symposium on Doping in Sport: Official Proceedings; 1989 Jun 5-7; Monte Carlo. Monte Carlo: International Athletic Foundation (IAF), 1990: 37–45
108.
go back to reference Cowan DA, Kicman AT, Walker CJ, et al. Effect of administration of human chorionic gonadotrophin on criteria used to assess testosterone administration in athletes. J Endocrinol 1991; 131: 147–54PubMedCrossRef Cowan DA, Kicman AT, Walker CJ, et al. Effect of administration of human chorionic gonadotrophin on criteria used to assess testosterone administration in athletes. J Endocrinol 1991; 131: 147–54PubMedCrossRef
109.
go back to reference De Boer D, De Jong EG, Van Rossum JM, et al. Doping control of testosterone and human chorionic gonadotrophin: a case study [published erratum appears in Int J Sports Med 1991; 12: 430]. Int J Sports Med 1991; 12: 46–51PubMedCrossRef De Boer D, De Jong EG, Van Rossum JM, et al. Doping control of testosterone and human chorionic gonadotrophin: a case study [published erratum appears in Int J Sports Med 1991; 12: 430]. Int J Sports Med 1991; 12: 46–51PubMedCrossRef
110.
go back to reference Laidler P, Cowan DA, Hider RC, et al. New decision limits and quality—control material for detecting human chorionic gonadotrophin misuse in sports. Clin Chem 1994; 40: 1306–11PubMed Laidler P, Cowan DA, Hider RC, et al. New decision limits and quality—control material for detecting human chorionic gonadotrophin misuse in sports. Clin Chem 1994; 40: 1306–11PubMed
111.
go back to reference Laidler P, Cowan DA, Hider RC, et al. Tryptic mapping of human chorionic gonadotrophin by matrix—assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 1995; 9: 1021–6PubMedCrossRef Laidler P, Cowan DA, Hider RC, et al. Tryptic mapping of human chorionic gonadotrophin by matrix—assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 1995; 9: 1021–6PubMedCrossRef
112.
go back to reference Liu CL, Bowers LD. Immunoaffinity trapping of urinary human chorionic gonadotropin and its high—performance liquid chromatographic—mass spectrometric confirmation. J Chromatogr B 1996; 687: 213–20CrossRef Liu CL, Bowers LD. Immunoaffinity trapping of urinary human chorionic gonadotropin and its high—performance liquid chromatographic—mass spectrometric confirmation. J Chromatogr B 1996; 687: 213–20CrossRef
113.
go back to reference Gam LH, Tham SY, Latiff A. Immunoaffinity extraction and tandem mass spectrometric analysis of human chorionic gonadotropin in doping analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 792: 187–96PubMedCrossRef Gam LH, Tham SY, Latiff A. Immunoaffinity extraction and tandem mass spectrometric analysis of human chorionic gonadotropin in doping analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 792: 187–96PubMedCrossRef
114.
go back to reference Götherström G, Bengtsson BA, Sunnerhagen KS, et al. The effects of five—year growth hormone replacement therapy on muscle strength in elderly hypopituitary patients. Clin Endocrinol (Oxf) 2005; 62: 105–13CrossRef Götherström G, Bengtsson BA, Sunnerhagen KS, et al. The effects of five—year growth hormone replacement therapy on muscle strength in elderly hypopituitary patients. Clin Endocrinol (Oxf) 2005; 62: 105–13CrossRef
115.
go back to reference Healy ML, Gibney J, Russell-Jones DL, et al. High dose growth hormone exerts an anabolic effect at rest and during exercise in endurance—trained athletes. J Clin Endocrinol Metab 2003; 11: 5221–6CrossRef Healy ML, Gibney J, Russell-Jones DL, et al. High dose growth hormone exerts an anabolic effect at rest and during exercise in endurance—trained athletes. J Clin Endocrinol Metab 2003; 11: 5221–6CrossRef
116.
go back to reference Berggren A, Ehrnborg C, Rosen T, et al. Short—term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH—insulin—like growth factor I axes. J Clin Endocrinol Metab 2005; 90: 3268–73PubMedCrossRef Berggren A, Ehrnborg C, Rosen T, et al. Short—term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH—insulin—like growth factor I axes. J Clin Endocrinol Metab 2005; 90: 3268–73PubMedCrossRef
117.
go back to reference Wu Z, Bidlingmaier M, Dall R, et al. Detection of doping with human growth hormone. Lancet 1999; 353: 895PubMedCrossRef Wu Z, Bidlingmaier M, Dall R, et al. Detection of doping with human growth hormone. Lancet 1999; 353: 895PubMedCrossRef
118.
go back to reference Powrie JK, Bassett EE, Rosen T, et al., on behalf of the GH−2000 Project Study Group. Detection of growth hormone abuse in sport. Growth Horm IGF Res 2007; 17: 220–6PubMedCrossRef Powrie JK, Bassett EE, Rosen T, et al., on behalf of the GH−2000 Project Study Group. Detection of growth hormone abuse in sport. Growth Horm IGF Res 2007; 17: 220–6PubMedCrossRef
119.
go back to reference Saugy M, Robinson N, Saudan C, et al. Human growth hormone doping in sport. Br J Sports Med 2006; 40: 35–9CrossRef Saugy M, Robinson N, Saudan C, et al. Human growth hormone doping in sport. Br J Sports Med 2006; 40: 35–9CrossRef
120.
go back to reference Voy R. Drugs, sport and politics. Champaign (IL): Leisure Press, 1991 Voy R. Drugs, sport and politics. Champaign (IL): Leisure Press, 1991
122.
go back to reference Savulescu J, Foddy B, Clayton M. Why we should allow performance—enhancing drugs in sport. Br J Sports Med 2004; 38: 666–70PubMedCrossRef Savulescu J, Foddy B, Clayton M. Why we should allow performance—enhancing drugs in sport. Br J Sports Med 2004; 38: 666–70PubMedCrossRef
123.
go back to reference Kayser B, Mauron A, Miah A. Viewpoint: legalisation of performance—enhancing drugs. Lancet 2005; 366 Suppl. 1: S21CrossRef Kayser B, Mauron A, Miah A. Viewpoint: legalisation of performance—enhancing drugs. Lancet 2005; 366 Suppl. 1: S21CrossRef
124.
go back to reference Noakes TD. Should we allow performance—enhancing drugs in sport? A rebuttal to the article by Savulescu and colleagues. Int J Sports Sci Coach 2006; 4: 289–316CrossRef Noakes TD. Should we allow performance—enhancing drugs in sport? A rebuttal to the article by Savulescu and colleagues. Int J Sports Sci Coach 2006; 4: 289–316CrossRef
Metadata
Title
Anabolic Steroid Use
Patterns of Use and Detection of Doping
Authors
Michael R. Graham
Bruce Davies
Fergal M. Grace
Andrew Kicman
Prof Julien S. Baker
Publication date
01-06-2008
Publisher
Springer International Publishing
Published in
Sports Medicine / Issue 6/2008
Print ISSN: 0112-1642
Electronic ISSN: 1179-2035
DOI
https://doi.org/10.2165/00007256-200838060-00005

Other articles of this Issue 6/2008

Sports Medicine 6/2008 Go to the issue